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ABSTRACT 
Human neonates are markedly more susceptible to infection than are older children or 
adults. This increased susceptibility is generally believed to be due to immaturity of the 
immune system to combat pathogens in both quantitative and qualitative terms. 
Therefore, it is important to understand the pattern of immune response present at early 
age in children. This study was conducted to observe the development of the immune 
system in newborns and infants of different ages. For this purpose, 50 participants were 
selected and divided into five groups as newborns, 6, 12 , IS and 24 months of age (for 
each group, the sample size was n= IO). The Tcell proliferation response to tetanus toxoid 
CIT) was considerably low in newborns than in children of other age groups whereas 
differences in PHA response were not significantly different. The distribution of T-cell 
and B-cell specific surface proteins clusters of differentiation (CD) markers on 
lymphocytes of participant newborns and infants were analyzed, The percentage of CD3+ 
T cells were significantly less in newborns than in children 6 months (P< 0.000 1),12 
months (P< O.OOOI),IS months (P= 0.001) and 24 months (P< 0.0001) old children 
while age-dependent gradual decrease was seen in % of CD3+CD4+ (T helper cells) and 
% of CD3+CDS+ (cytotoxic T cells) and their ratio (CD4+/CDSl where % of CD 19+ B 
cells were much elevated in older age groups than in newborns. Cholera toxin (Cn of 
Vibrio cholerae specific plasma IgA response was found notably low in newborns than in 
6 months (P= 0.0003), 12 months (P= 0.000 I), IS months (P= 0.000 I), and 24 months 
(P= 0.0001) aged children. When compared with 6 month old infants with those that 
were 12 months (P= 0.02), IS months (P= 0.029), and 24 months of age (P= 0.007) the 
CT- IgG response was elevated in 24 months children than newborns (P< 0.0001) and 6 
months infants (P= 0.03). Similarly the IgA and IgG response was seen against the heat 
labile toxin (L T) of Escherichia coli. Significantly high tetanus toxoid (TT) specific IgG 
response was seen in newborns than in those 6 months (P= 0.04), 12 months (P= 0.02), 
IS months (P= 0.007) and 24 months (P= 0.02) of age. In contrast, measles virus specific 
IgG was distinctly high in 6 months (P= 0.00 I), 12 months (P= 0.03), IS months (P= 
0.009) and 24 months (P= 0.015) old children when compared to newborns using cord 
blood analyses. A base line level vibriocidal antibody response was observed in the 
study children . The fecal IgA response was comparable among the infant' groups where 
heat-labile toxin (L T) fecal [gA was found to be lower in the 6 and 18 months old 
children, although it was significantly elevated in those 12 and 24 months old children 
(p= 0.021). This study demonstrated that the maturation of the immune system is 
mirrored in cellular and humoral immune responses to specific antigens and minimizes 
the developmental limitations with growing age during infancy. 
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INTRODUCTION 
iNTRODUCTiON 
1.1 Background 
For the newborn, birth is a major physiological event, with its transition from a state of 
intrauterine environment to one of ex utero independence. At this time, the immune 
system faces the challenge of transferring from a sterile environment, in which the 
responsibility is on avoiding responsiveness, to a world of microbes where protection is 
vital. 
The neonate, whether premature or of normal gestational age, is a unique host from an 
immunologic perspective. Many components of the immune system funct ion less well in 
neonates compared with adults, giving rise to the concept of an "immunodeficiency of 
immaturity"{Schelonka, 1998 #290}, although it has recently been confirmed that the 
neonatal immune system not to be immature but rather specifically adapted for early 
stages of life {Wood, 201 I #291}. 
Considering the importance of neonatal immune capability in influencing predisposition 
to infection, till date, little work has been done on adaptation of the immune system to 
these changed circumstances. 
However, several factors are conspiring to focus attention on neonatal immunology. 
First, the belief that neonatal exposure to antigen results in tolerance rather than 
immunity has been challenged {Ridge, 1996 #160} . Second, in reducing infant morbidity 
and mortality, development of effective neonatal vaccines is likely to be extremely 
important {Marshall-Clarke, 2000 #7}. Third, recent evidence suggests that exposure to 
high levels of antigen during early life might contribute to the increasing prevalence of 
various diseases in adulthood. 
The greatest burden of morbidity and mortality from infectious diseases occurs in 
children under 5 years of age. Of the 8.2 million under-five child deaths per year 
globally, about 3.3 million occur during the neonatal period, in the first four weeks of 
life, with the highest rates occurring in resource-poor countries. It is especially in Africa 
and South Asia that the least progress in reducing neonatal deaths has been made {lmtiaz 
Jehan, 2009 #206}. 
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As Millennium Development Goals (MGDs) adopted by the United Nations (UN) in 
2000, aim to decrease by two-thirds child deaths worldwide by 2015, therefore, efforts 
are focused on reducing neonatal deaths in high-mortality countries to achieve the goal. 
Furthermore, vaccines designed/optimized for early life immunization may reduce infant 
mortality and morbidity. Efforts should be made to promote its use at a global level. 
1.2 Immune System - An Overview 
The immune system is a complex array of defense mechanism that relies mainly on the 
ability to distinguish between the host and foreign elements. It is composed of specific 
cells, soluble mediators and specialized organs to protect our body from foreign 
pathogens. The immune response initially recognizes the type of pathogen and 
secondarily must mount a protective immune reaction to eliminate the pathogen {Roitt I, 
2001 #154} {Adkins B, 2004 #16}. 
IMMUNITY 
INNATE 
r, llO<"J AC U R(O 
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Figure 1.1: Divisions of immunity- Innate and Adaptive 
[http://www.biology.arizona.edulimmunology/tutorialslimmunology/page3.ht 
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Immune system composed of mainly two types of immunity 
> Innate or non specific immunity 
> Adaptive or specific immunity 
1.2.1 Innate immunity 
The innate immune system is made up of many cells, humoral factors, and the surface 
barrier, and it is a universal and evolutionarily ancient form of host defenses{Trinchieri, 
1995 #95 }{ Underhill, 2002 #97}{Gantner, 2003 #98}{Moynagh, 2005 #99}{Chirico, 
2005 # 163}. However, most cells of the innate immunity contribute to the antigen 
processing and presentation { La Pine TR, 2004 # 165} {Zaghouani, 2009 # 171 }. 
Innate immune responses are triggered by bacteria, viruses, protozoa, and fungi , as non-
self, and involve nonspecific activation of different cells and complement {Marodi , 2006 
# I I} (Fig-1.2). 
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Figure 1.2: Distinct though mutually coordinated Innate and adaptive immunity 
http://www.rikenresearch.riken.jp/engffrontline/5028 
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1.2.2 Adaptive immunity 
The adaptive immune system has evolved to protect humans from a continuous onslaught 
of infectious microbes, and the system must respond to an enormous diversity of foreign 
antigens while avoiding accidental responses against self antigens. T and B lymphocytes, 
antibodies, natural killer cells, colony stimulating factors, T cell derived effector and 
immunoregulatory cytokines, and Lnterferon-y, and are the main components of the 
adaptive immunity {Chirico, 2005 #163}. However, innate recognition of pathogens is 
the first step in inducing adaptive immunity {Janeway, 2002 # 112} and producing 
memory which ensures both stronger and more rapid immune response to the antigen 
during re-exposure even years after the initial encounter {David A. Randolph, 2005 
#211 }. 
1.3 Development of Immune Response 
The first stage of human fetal haemopoiesis occurs in the mesoderm of the yolk sac and 
the extra embryonic mesenchymal tissue {Holt, 2000 #83}. After birth, there is an age-
dependent maturation of the immune response. Of note, prenatal and postnatal exposure 
to environmental microbial products that can activate innate immunity might accelerate 
this maturation process, particularly if the exposure occurs repeatedly over time {Ng, 
2006 #148}. Defects of neonatal adaptive immunity which requires experience with 
antigens, defects in innate immunity are more elusive as, in contrast to adaptive 
immunity, the innate immune system does not require immunologic experience to 
function well {Marodi, 2006 #2}.However, more recent experiments have proven that, 
under the right conditions, the neonatal immune system generates responses similar in 
strength and quality to those ofadults{David A. Randolph, 2005 #211}. 
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Table 1.1: Some functional development during immune system development {Paul A. 
Offit, 2006 # 138} 
;\\aternal 
protection from 
breast milk 
Difference durin!! infllncy 
Phagocytes cannot migrate towards 
infectious sites, although their 
bactericidal activity is normal. 
Poor production of cytokines, in 
particular Th I cytokines such IFNy 
by T-cells. 
Is incomplete, probably caused by 
immaturity in cytokine production 
ofT cells and monocytes 
Slow response to infection 
Impaired responses of other cell 
populations that rely on their 
functions such as natural killer cells. 
Inefficient killing of viruses 
Develops progressively during the Inefficient phagocytosis 
first year of life 
NaiVe T and B cells first appear in 
key organs from an early point in 
fetal development 
Impaired production of some 
isotypes. Low serum IgM, IgA and 
IgE. IgG mostly of maternal origin. 
IgG against some infectious 
organisms crosses the placenta. 
Wanes during first year of life. 
Mostly IgA 
Repeated antigenic stimulation leads 
to the complete maturation of 
specific immunity during the first 
few years of life. 
Inability to respond to 
polysaccharide encapsulated bacteria 
until about 2 years of age. 
Gives protection against some 
infections that mother exposed to or 
immunized against including measles 
and meningococcal disease. Can 
interfere with vaccines such as 
MMR. 
Provides additional protection 
against gut microbes, less effective 
against respiratory infections 
v 
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1.4 Neonatal Immune System 
The infants' immune system is intact but immature at birth. The fetal and neonatal 
immune systems are associated with physiological demands that are three-fold {Levy, 
2007 #15}. 
First, protection against infection, including viral and bacterial pathogens at the 
maternal- fetal interface {Klein, 2001 # 140}{McDonagh, 2004 # 139} ; 
Second avoidance of potentially harmful pro-inflammatory/T helper I (TH I)-cell 
polarizing responses that can induce alloimmune reactions between mother and fetus 
{Makhseed, 200 I # 141} and 
Third mediation of the transition between the normally sterile intra-uterine environment 
to the foreign antigen-rich environment of the outside world, including primary 
colonization of the skin{Marchini, 2005 #142} and intestinal tract{Karisson , 2002 
# 143 }by microorganisms. 
The neonates are markedly more susceptible to infection than are older chi Idren or adults 
{Lewis DB, 1995 # 120}{ME, 1978 # 121}. Hence, a number of hypotheses have been 
proposed to explain this phenomenon including: 
~ antigenic inexperience {Chirico, 2005 #163} , 
~ a lack of pre-existing antibody; {Trivedi, 1997 # I 19} , 
~ decreased complement levels {Lewis DB, 1995 #120}, {Baker, 1976 #117} 
deficient phagocytic cell function {Weston, 1977 #123} , 
~ immature T cell function {Lewis DB, 1995 # 120} {Zola, 1995 # 124} , 
~ decreased numbers of CD45ROI cells {Clement, 1988 #127} {Pirenne, 1992 
# 128} and 
~ the prevalence of suppression factors {Chirico, 2005 # 163}. 
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1.4.1 Neonatal Innate Immune Response 
Given the limited exposure to antigens in utero and the well-described defects in neonatal 
adaptive immunity{Adkins B, 2004 # 16}, newborns must rely on their innate immune 
systems for protection to a significant extent{Krishnan, 2003 # 144}{Firth, 2005 #145}. 
Biasing fetal immunity toward Th2 polarization than Th I {Firth, 2005 #145} {Marodi, 
2006 #2} appears to be an evolutionary adaptation orchestrated via production of 
cytokines and other regulatory molecules to protect placental and fetal damage through 
spontaneous abortion. {Nicolaos Vitoratos, 2006 #146}{Roth, 1996 #103}{Szekeres-
Bartho, 2002 #106}{Piccinni, 1995 #104}. In contrast, predominant production of Th2 
cytokines in feta l and neonatal life plays a key role in damping the newborn ' s innate 
immune responses. {Wegmann, 1993 # I 0 I}. 
1.4.2 Neonatal Adaptive Immune Response 
As the innate immune system can instruct the adaptive immune response {Janeway, 2002 
# 112} , distinct functional expression of neonatal innate immunity, including a bias 
against Th I-cell-polarizing cytokines, contributes to a distinct pattern of neonatal 
adaptive immune responses {Levy, 2007 #15} . Passively acquired antibodies can alter 
the humoral and antibody-dependant (B cell mediated) response to immunogens for up to 
18 months in infants of infected or immunized mothers; in contrast, cellular immune 
responses (T cell mediated) appear unaffected by maternal antibody {Siegrist, 1998 #39} 
{Siegrist, 1998 #20}. 
Adaptive immune response is generally mediated by two distinct mechanisms in neonates 
like the adults .Theyare; 
./ Cellu lar or T cell mediated adaptive immune response 
./ Humoral or B cell mediated adaptive immune response 
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1.4.2.1Cellular or T cell mediated neonatal adaptive immune response 
The neonatal T cells are generally na"ive. The fetal-neonatal predominant functionally 
immature naIve phenotype is likely to be related to the absence of antigenic stimulation in 
the germ free intrauterine environment{Gasparoni, 2003 #170}{Clement, 1988 
# I 27}{Pirenne, 1992 # 128} Neonatal T cells are easily induced to proliferate by 
homeostatic signals, but they appear to be more difficult to activate fully through the 
TCR due to reduced density of surface TCR complexes, CD40-ligand expression{DB., 
2004 # 167} and lack of APC interaction molecules{Schonland, 2003 #2 13} {Harris, 1992 
# 173} resulting in delayed differentiation ofna"ive T cell into Thl effector cells and poor 
cytokine production{Bryson, 1980 #92}. Moreover, induction of cytotoxic T lymphocyte 
(CTL) response is age-dependant and is impaired in infants {Chiba, 1989 # 132} , though 
maturation appears to occur within the first year of life {Siegrist, 200 I #I} (Fig 1.3). 
T helper cell 
? 
T helper cell B cells 
04+ ~ T helper cell 
.. 
CD4+ )- .. • 
APe 
• Antigen 
macrophages 
Killer T cells 
Antibodies 
Figure 1.3: Mechanisms ofT cell mediated cellular and B cell mediated humoral 
immune response [http://en.wikipedia.orglwiki/File:Lymphocyte_ activation _ simple.pngj 
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1.4.2.2 Humoral or B cell mediated neonatal adaptive Immune 
response 
In the neonatal period, humoral or B cell mediated adaptive immune response i.e 
antibody response is relatively weak as infants largely depend on transplacentally 
acquired maternal IgG during gestation and IgA from breast milk {Marodi, 20 I 0 # I 2} 
(Fig 1.3). However, three potential problems are consistently found that may contribute 
to the overall poor antibody responses; 
1) T-cell help may be inadequate due to down regulated CD40 ligand leading to impaired 
immunoglobulin class switching {Jullien, 2003 #218}{Han, 2004 #2 I 9}{Stavnezer, 1996 
# 179}. 
2) Neonates have relatively low levels of complement, and B cells complement receptors 
{Siegrist, 2001 #I}. 
3) The lymphoid structures necessary to optimize B-cell function may not be operational 
in the neonatal period {David A. Randolph, 2005 #2 I I} resulting in low avidity 
antibodies. 
In contrast, there are some potential evolutionary factors that limit plasma-cell 
differentiation in early life {Siegrist, 2009 #26}. These are as follows: 
• Antibodies of maternal origin decrease the antigen load and provide protection, so there 
is no drive for plasma-cell differentiation 
• Preventing plasma-cell differentiation until memory B cells have been primed and/or 
reactivated could limit potentially harmful cross-reactive responses to self 
polysaccharides and glycosylated proteins during the vulnerable periods of feta l and 
postnatal development 
• As a mechanism to limit responses against prevalent but harmless environmental 
antigens (resource sparing) 
• As a mechanism to prepare the post-weaning period for prompt reactivation in case of 
repeat exposure. 
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1.5 Maturation of Immune System with Age 
Neonatal age is characterized by a delicate process of adaptation from intra- to extra-
uterine life. The immune system is particularly subject to problems of adaptation to the 
new environment. Neonates differ from adults at virtually every step toward an effective 
Immune responses. 
The most important difference between neonatal responses and adult responses is the 
inability to mount rapid {Holt, 2000 #83}, strong memory responses {David A. 
Randolph, 200S #211 }because neonates are immunologically nM've having fewer 
antigen-specific T-cell precursors, hard to stimulate with immature APCs {Jaspan, 2006 
#13S} {Hassan, 1996 #24} {Shearer, 2003 #2S}and once activated, neonatal T cells 
produce fewer cytokines than an adult and are predisposed toward Th2 responses than 
robust Th I response producing various Th I cytokines {Marodi, 2006 #2} usually found 
in adults {Adkins, 1999 #177} . 
In contrast to mature, adult B cells, immature B cells are negatively signalled by ligation 
of the B-cell receptor (BCR) and fail to upregulate co-stimulatory molecules (such as 
CD86), lead to CD40 ligand (CD40L) induction {Brugnoni, 1994 #162} different 
adhesion molecules {Tasker, 2003 #220}and MHC class 1\ molecules that are essential 
for effective interaction with T cells through T-cell receptors (TCR){King, 1999 #ISI} 
{Marshall-Clarke, 2000 # IS2} {Benschop, 200 I # IS3} (Fig 1.4). 
Many studies have shown that the primary T-cell-dependent antibody responses induced 
in the neonatal period differ from adult responses {Marshall-Clarke, 2000 #7}{Siegrist, 
200 I # I}. Neonatal antibody responses are delayed at onset, reach lower peak levels, are 
of shorter duration, lower distribution of IgG2 isotype and are of lower average affinity 
{Schallert, 2002 #ISO}{Janeway CJr, 1999 #134}and reduced heterogeneity than that of 
adults. 
-
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Figure 1.4: A model of the poss ible effects of differences in signalling between adult and 
neonatal B cells on the outcome ofT - B interactions. 
In addition to quantitative differences in antibody production during early life versus 
adulthood, there are also qualitative differences. B lymphocytes from newborns can be 
made to synthesize IgM at adult levels, but not IgG and IgA . Within 24 months from 
birth the secretion of IgG has reached adult capacity whereas IgA formation is still 
diminished {Andersson, 1981 # 185} {JanewayeJr, 1999 # 134}. 
-
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1.6 Neonatal Vaccine Response 
The aim of vaccination is to rapidly elicit protective immunity and generate memory 
cells, which respond rapidly and strongly to subsequent antigen exposure {Bjarnarson, 
2005 #3}. The ideal vaccine would be a single dose given at birth, preferably avoiding 
injections, and providing immediate and long-lasting protection against multiple diseases 
{Wood, 2011 #29 1} . 
The longer-term effectiveness of a vaccine is determined by a combination of 
~ persistence of antibody {Snape, 2008 #31} , 
~ immunological or B cell memory (here defined as the ability to make a secondary 
response to re-exposure to the antigen) {Kelly, 2005 #32} and 
~ persistence of herd immunity, which reduces transmission of the organism in the 
population{Maiden, 2008 #33} {Pollard, 2009 #34}. 
Most children in the world receIve their primary immunizations in the Expanded 
Programme on Immunization (EPI) schedule at 6, 10 and 14 weeks of age because 
infectious diseases cause the highest morbidity and mortality rates in early life {Pollard, 
2009 #34}. 
Infant vaccine studies worldwide have shown that there is an age-dependent stepwise 
increase in the rates of seroconversion and the magnitude of antibody responses, 
regardless of whether repeat immunization is administered{Halsey, 1985 #27}{Einhorn, 
1986 #28} . 
At birth, immune responses to protein antigens are much greater than responses to 
glycoprotein and polysaccharide antigens {WP, 2001 # 19}. Responses gradually improve 
by 6-9 months of age for glycoproteins and by 12-24 months for polysaccharides {WP, 
2001 # 19} . 
-
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Optimization of vaccine-induced protection of infants against pathogens to which 
they are exposed within the first weeks and months of life requires one to avoid 
limitations linked to 
(i) the induction of weaker, shorter or biased immune responses in infancy and 
(ii) the presence of preexisting antibodies of maternal origin to protect the newborn 
from various infections. In most circumstances, similar specific antibody titres to 
vaccine antigens, like tetanus toxoid (TT) and measles are observed in mothers and 
newborns which have been linked to failure of infant responses to vaccines, 
resulting in a window of susceptibility to infectious disease {Osborn, 1952 #244}. 
The immunogenicity of many vaccines in infancy is increased when; 
./ immunization starts later (less interference from maternal antibody){O'Brien, 
2007 #55} {Tiru, 2000 #30} 
./ more doses are given {Booy, 1992 #29} and 
./ there is a greater length of time between doses {Taranger, 1999 #56} 
{Giammanco, 1998 #57} {Carlsson, 1998 #58}. 
Although, neonatal immunization does not generally lead to rapid antibody responses; 
however, it may result in efficient immunologic priming which can act as a basis for 
future responses {Chirico, 2005 # 163}. 
Current vaccines mediate their protective efficacy through the generation of neutralizing 
antibodies {Siegrist, 2009 #26}. But one of the limitations of current vaccine 
mechanisms is due to short duration of antibody responses elicited before 12 months of 
age. Most vaccinated infants have low or undetectable vaccine antibody concentrations as 
early as 6-9 months after completion of the primary immunisation series, requiring 
administration of a booster dose in the second year of life {Siegrist, 2001 #I }. More 
recently, certain vaccine delivery systems with adjuvants have been found to provide 
more sustained protection against various diseases {BP, 200 I #21}. 
-
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1.7 Vaccine Specific Immune Response 
1. 7.1 Measles 
Measles, also known as Rubeola, is an infection of the respiratory system caused by 
a virus, specifically a paramyxovirus of the genus Morbillivirus. Measles is spread 
through respiration (contact with fluids from an infected person's nose and mouth, either 
directly or through aerosol transmission), and is highly contagious - 90% of people 
without immunity sharing living space with an infected person will catch it. The infection 
has an average incubation period of 14 days (range 6-19 days) and infectivity lasts from 
2-4 days prior, until 2- 5 days following the onset of the rash. 
1.7.1.1 Epidemiology of measles 
According to the World Health Organization (WHO), measles is a leading cause of 
vaccine-preventable childhood mortality. Worldwide, the fatality rate has been 
significantly reduced by a vaccination campaign led by partners in the Measles Initiative: 
the American Red Cross, the United States Centers for Disease Control and Prevention 
(CDC), the United Nations Children's Fund (UNICEF) and the World Health 
Organization (WHO). Globally, measles fell 60% from an estimated 873,000 deaths in 
1999 to 345,000 in 2005 {Helfand, 2008 #61}. Estimates for 2008 indicate deaths fell 
further to 164,000 globally, with 77% of the remaining measles deaths in 2008 occurring 
within the South-East Asian {WHO, 4th December 2009 #62} . 
In Bangladesh, Measles is the fifth leading cause of death among children under five 
years of age. Annually, an estimated 20,000 children die from measles in this country 
which has a population of around 160 million. 
14 
iNTRODUCTION 
1.7.1.2 Measles vaccine: The MMR vaccine 
The Measles Mumps Rubella (MMR) vaccine is an injection that prevents us from 
catching measles, mumps and rubella. Although people usually recover from these 
illnesses, each one can be unpleasant and have serious consequences. 
MMR is a live attenuated vaccine. This means that it contains the living viruses, which 
have been altered in such a way as to prevent the vaccine from actually causing the 
diseases. However, the body's immune system still responds to it, providing future 
protection against infection. 
Recommendations for measles immunisation have accordingly traditionally been based 
on age of MatAb disappearance for the majority of infants {Wi lliams, 1995 #37}. 
« !lO " 
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Figure 1.5: Immunization coverage with measles containing vaccines in infants, WHO 
2007 [http://en.wikipedia.orglwiki/File:Measles_vaccination _ worldwide.png] 
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1. 7.1.3 MMR vaccine timetable 
The MMR vaccine is usually given to children, who have the first injection when they are 
about 10 (9-IS) months old. A second dose is given between the ages of three and five 
• years to cover any children who haven't responded to the first one. 
Table 1.2: The recommended immunization schedule for Measles 
Ale VacdJle Doee 
9-15 months Measles, mumps and rubella One injection (Trivomax®) 
(MMR) 
3 years - 5 years Measles, mumps and rubella One injection (Trivomax®) 
(MMR) 
1.7.1.4 Measles Vaccine Response 
The early priming is likely to explain the reduced measles morbidity and mortality 
observed in vaccinated infants as an age-dependent stepwise increase is observed in rate 
of seroconversion and antibody concentrations following measles immunization at 6, 9, 
12 or IS months of age {Johnson, 1994 # 1 82}{Gans, 1998 #S2}{Cherry, 1973 
#210}{Siegrist, 1998 #39}{Albrecht, 1977 #42}. In contrast it was recently suggested 
that immunization < 12 months of age may be associated with waning immunity against 
measles in West Africa {Siegrist, 1998 #20}. 
Presence of very high neutralizing MatAb/antigen ratio could eventually result in 
complete neutralization of MMR vaccine load, preventing in-vivo replication and thus 
reducing the effective immunizing dose below the immunogenicity threshold required for 
induction of antibody responses without disturbing T cell response{Siegrist, 200 I 
# I }{Gans, 1998 #S2}{Gans, 1999 #S3} as measles immunization of 6-month-old infants 
in presence of MatAb led to positive antibody responses in only 36.7%, whereas positive 
T-cell responses were measured in 86.8% {Pabst, 1999 #S4}. 
-
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1. 7.2.1 Tetanus 
Tetanus is an acute and often fatal disease caused by tetanospasmin, an extremely 
potent neurotoxin produced by Clostridium tetani. The bacterial spores are deposited in 
tissue, usually by traumatic injury, retained placenta or endometrial injury and under 
anaerobic conditions vegetate. The muscle spasms cause a stiff gait, rigid posture, 
extension or elevation of the tail, protrusion of the third eyelid and trismus. Spasms of 
facial muscles cause abnormally erect ears and retraction of the lips that resembles the 
'risus sardonicus' seen in humans with tetanus. Stimulation precipitates generalized 
muscle contractions and tetanic spasms or convulsions. The disease can be prevented 
by immunization with tetanus toxoid or the use of antitoxin. 
l. 7.2.2 Epidemiology of Tetanus 
Tetanus is a vaccine-preventable disease that yearly causes a total of 309,000 deaths 
{Vandelaer, 2003 #229} as C. tetani spores are ubiquitous. The disease occurs almost 
exclusively in persons who are unvaccinated or inadequately immunized {Wells CL, 
1996 #62}. Tetanus - particularly the neonatal form - remains a significant public health 
problem in non-industrialized countries. As about 1.4 million neonates die yearly in the 
first 4 weeks after birth {WHO,2000 #228}.The World Health Organization 
(WHO) estimates that 59,000 newborns worldwide died in 2008 as a result of neonatal 
tetanus {WHO, 2010 #64}. 
In Bangladesh, one of the world's least developed countries, over 80% of women give 
birth without any help from a skilled birth attendant. In the mid-1980s, Bangladesh had 
one of the highest rates of neonatal tetanus in the world: 41 cases for every 1000 live 
births {Hlady, 1992 #65}. Only 5% of women of childbearing age were immunized with 
tetanus toxoid and only 5% of pregnant women had access to a clean birth. Not 
surprisingly, neonatal tetanus accounted for one in four infant deaths. 
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Today, Bangladesh has succeeded in reducing death rates from 41 for every 1000 live 
births in 1986 to only 4 per 1000 by 1998. And in a final push to reach the WHO global 
target for elimination of neonatal tetanus is less than one neonatal tetanus death per 1000 
live births in every district in every country{Group, 1994 #230}. 
1.7.2.3 Tetanus vaccine 
Tetanus vaccine (Tetanus toxoid) is a vaccine used against Clostridium tetani, the agent 
that causes tetanus. It is a component of the DPT vaccine. This vaccine is for 
intramuscular or subcutaneous use; is a sterile solution of toxoid in isotonic sodium 
chloride solution. The tetanus vaccine is required again after 10 years if the individual is 
exposed to possible infection. 
Tetanus vaccine was first deployed in the 1930s, and it is now well established that at 
least five doses of this vaccine should be administered to provide long-term protection 
{Pollard, 2009 #34}). 
Tc li:.nU5 b a c; lO llii 
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Fig 1.6: Production of Tetanus toxoid vaccine from emitted toxin of Clostridium 
tetani by chemical modification [Source: HealthSoft, Inc, USA] 
Tetanus toxoid, given as Tetanus vaccine is chemical conjugation of the polysaccharide 
to a protein carrier --directs processing of the protein carrier by polysaccharide-specific 
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B cells and presentation of the resulting peptides to carrier-peptide-specific T cells in 
association with MHC class II molecules. So, a conjugate polysaccharide vaccine induces 
a T-cell-dependent response from early infancy and induces an anamnestic (memory) 
response to a booster dose of the vaccine ({Kelly, 2006 #36}. 
1.7.2.4 TT vaccine timetable 
The TT vaccine is usually given to children, who have the first injection when they are 6 
weeks old. Two more doses are given between the ages of two and six month and a 
booster dose ig given at 12 month of age. 
Table 1.3: The recommended immunization schedule for Tetanus 
Age Vaedne Dose 
6 weeks, I 0 weeks, 14 weeks DPT (Diptheria, Pertussis, One injection each time 
Tetanus) 
15 months (12 Months after DPT (Diptheria, Pertussis, One injection 
last dose) Tetanus) 
1.7.2.5 TT vaccine response 
Tetanus toxoid (TT), a protein antigen is able to elicit antibody response from neonates 
{Day, 2004 # 107} {Ku, 2005 # 108} {Orange, 2004 # 109}.Tetanus toxoid (TT) is known 
to induce a strong and long lasting humoral immune response in humans after vaccination 
{Wellhorner, 1981 #22 1} {Excler, 1998 #4}. After TT vaccination generates induction of 
clonal T cell response {Adams, 1991 #224}{Geha, 1973 #225}{Kabilan, 1990 #226}. It 
has been demonstrated that TT-specific T cells are mainly CD4+ cells secreting Thl 
cytokines such as IFN-y {Parronchi, 1991 #227}{Mayer, 2002 #5}. 
19 
iNTRODUCTiON 
Administration of a birth dose of tetanus toxoids (TT) vaccines usually fail to induce 
significant antibody responses to the first neonatal dose due to age-dependent limitation 
of infant antibody response. {Kurikka, 1995 # I 86}{Lieberman, 1995 # 187} {Dengrove, 
1986 #192} and presence of mate mal antibodies {Sarvas, 1992 #47}. 
Like other infectious disease antigens, IT stimulates a very robust T cell immune 
response that can easily be detected using a variety of assays {Goodell Y. , 2007 #246} , 
like lymphocyte proliferation assay (LPA). 
1.8 Mucosal Immune Response 
Mucosal immunity is characterized by a specific maturational pattern initiated in the 
intrauterine fetal development and continued during the neonatal period, and in infancy 
and childhood, dynamically leading to a highly specialized immune response as intestinal 
mucosa is in intimate contact with microbiota, the symbiotic ecosystem of more than 450 
species of mutualist and commensal microorganisms {Szczawinska-Poplonyk, 20 II 
#68}. The fundamental challenge of mucosal immune response is to prevent effectively 
the entry of invading pathogens, the development and the disseminating of infection 
whereas simultaneously its exposition to the external environment and to a high antigenic 
load that elicits immune tolerance {Szczawinska-Poplonyk, 2011 #68}. 
Mucosal immune response is generated to 
(i) protect extensively the mucous membranes against colonization and invasion by 
potentially dangerous microbes that may be encountered, 
(ii) prevent uptake of and 
(iii) prevent the development of potentially harmful immune responses to these 
antigens if they do reach the body interior {Holmgren, 2005 #79}. 
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IgA is the most important immunoglubulin in the intestine and other mucosal surfaces. 
The induction of IgA against mucosal pathogens and soluble protein antigens is 
dependent on T helper ce ll s {Lycke, 1987 #80} {Homquist, 1995 #81}, although IgA 
immunity to commensal flora may be thymus independent and of low affin ity {Stoel, 
2005 #82} . 
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Figure 1.7: Mechanism of Mucosal innate immune response 
[http://www.nature.com/nri/journal limages/nri 1439-fl.jpg] 
1.9 Neonatal Mucosal Immune Response 
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A functioning mucosal immune system is essential for survival in infancy and beyond 
{Holt, 2000 #83} {Thrane, 1991 #74} . At birth this system is quite immature, putting the 
newborn mammal at risk for a variety of infectious and noninfectious diseases. The 
mucosal surface is exposed to a huge antigenic challenge and the immature mucosal 
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immune system must learn to distinguish when a tolerogenic versus an immunogenic 
response is most appropriate {Vancikova, 2002 #133} . 
Despite the anatomical and functional immaturity of the mucosal immune system and 
crosstalk between innate and adaptive immune responses, infants and young children are 
capable of mounting effective immune defense mechanisms {Szczawinska-Poplonyk, 
20ll #68}. 
1.10 Maturing Mucosal Immune Response with Age 
The development of mucosal immunity in children is a time-dependent process initiated 
in the intrauterine growth and is continuous during the postnatal period {Szczawinska-
Poplonyk, 2011 #68}. With age and antigenic stimulation, maturation occurs and 
intestinal host defense then functions quite effectively to protect the host from ingested 
noxious substances and microorganisms {Mannick, 1996 #77}. 
The structures of the mucosal immune system are fully developed by the 28 gestational 
week and thus premature infants older than 28 weeks of gestation are capable of 
mounting an effective mucosal immune response {Gleeson, 2004 #7l} . Mucosal 
permeability is rapidly reduced within the first 48 hours after birth. In the oral mucosa 
disappearance of maternally-derived IgG retlects this postnatal mucous membrane 
closure {Gleeson, 1982 #70}. The rapid increase of innate defense factors , such as 
salivary lysozyme, lactoferrin and amylase during the first six postnatal months may 
provide the infant necessary protection during the period when specific adaptive 
immunity at mucosal sites is not fully developed {Thrane, 1991 #74}. 
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IgA-producing immunocytes, though increase in number during neonatal period and 
reach an initial peak about 4-6 postnatal weeks, they approach the low normal adult level 
at about 18 months of age, subsequently with small increase throughout early childhood 
{Maheshwari A, 2006 #73} and disease {Stoltenberg, 1993 #156} . 
1.1 0 Aim of the Study 
The aim of the study was to analyze the development of immune response in newborns, 
infants and children at different time point from birth to two years of age. The present 
study was conducted with the following specific objectives; 
• To observe the T cell proliferation response to tetanus toxoid (TT) and 
phytohemagglutinin (PHA) in study infants. 
• To differentiate the distribution ofT and B cell specific cluster of differentiation 
(CD) markers on lymphocyte of infants of different ages by flow cytometry (FACS). 
• To compare plasma IgA and IgG antibody response to cholera toxin (CT) of 
Vibrio cholerae among the children. 
• To estimate heat labi le toxin (L T) of Escherichia coli specific plasma IgA and 
IgG antibody responses. 
• To analyze vibriocidal antibody response in plasma. 
• To evaluate vaccine specific antibody responses to tetanus. 
• To assess vaccine specific antibody responses to measles. 
• To determine fecal antibody (lgA) response of the study infants. 
• To measure heat labile toxin (L T) of Escherichia coli specific fecal antibody 
(lgA) responses in enro ll ed participants. 
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METHODS AND MATERIALS 
2.1 Study Location 
This study was carried out in the Immunology Laboratory of the Centre for Vaccine 
Sciences at the International Centre for Diarrhoeal Disease Research, Bangladesh 
(icddr,b). 
2.2 Study Area and Subjects 
The study area of this investigation was in Mirpur in Dhaka city. Specimens were 
obtained from forty infants from newborn and four other age groups (6 month, 12 month, 
18 month and 24 month; ten in each group). Ten cord blood specimens from newborns 
during delivery were also collected to serve as ' newborn specimen" for this study. All 
forty infants were healthy (without any symptoms of diarrhea or acute respiratory 
infection). Stools were tested to confirm the healthy status of the children. 
2.3 Study Design 
The study participants were divided into the following categories based on their age 
Group I II III IV V 
Age (months) 0 6 12 18 24 
(Cord Blood 
specimens) 
Number of infants 10 10 10 10 10 
All the children of the above four categories (except newborns from whom cord blood 
was collected) were vaccinated under the Expanded Program of Immunization (EPI) 
schedule which also included vaccines for Tetanus and Measles. 
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The study groups were compared in the following parameters: 
• T-cell Proliferation response to tetanus toxoid (Tf) and phytohemaglutinin (PHA) 
• Distribution of T-cell and B-cell specific Surface proteins clusters of 
differentiation (CD) markers on lymphocytes 
• Cholera Toxin (CT) specific plasma Immunoglobulin G (lgG) and 
Immunoglobulin A (IgA) responses 
• Heat labile toxin (L T) of Escherichia coli specific plasma IgG and IgA responses 
• Vaccine specific plasma IgG immune response to Tetanus 
• Vaccine specific plasma IgG immune response to Measles 
• Plasma Vibriocidal Antibody response 
• Fecal totallgA profile 
• Heat labile toxin (L T) of Escherichia coli specific fecallgA response 
The design of the study plan for immunological analyses is shown in Fig 2. I 
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Fig 2.1: The design of the study plan 
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2.4 Collection of Specimen 
About 3ml venous blood for each child was collected in sterile, rubber capped vacutainer 
(Beckton Dickinson, BD, USA). The stool samples were collected in sterile plastic 
containers and stored at -70 °C for further analyses. 
2.5 Laboratory Methods 
2.5.1 Isolation of cord blood mononuclear cells (CBMC) and 
Peripheral blood mononuclear cells (PBMC) 
Peripheral blood mononucIearcells (PBMCs) were isolated from venous blood by density 
gradient centrifugation on Ficoll Isopaque (GE Healthcare, Uppsala, Sweden). As the 
density of red blood cells (RBC) is higher than PBMC, RBC is precipitated. The plasma 
remains in the upper portion. Isolated PBMCs were incubated in 96-well tissue culture 
plates at 37°C in 5% C02. The T-cells sensitized with antigens secrete cytokines during 
the culture period. The culture supernatants were preserved for the detection of various 
inflammatory and pro-inflammatory cytokines as well as other immunomodulators. 
Procedure 
a) Heparinized cord/venous blood was diluted with equal volume of Phosphate Buffered Saline 
(PBS; 10 mM, pH 7.2) in Falcon tubes (Beckton Dickinson, BD). 
b) Diluted blood was carefully added onto half the volume of Ficoll-Isopaque (GE Healthcare, 
Uppsala, Sweden) without disturbing the Ficoll layer. Hence, two distinct layers were 
maintained. N 
c) The tube was centrifuged at 772g for 25 minute at 20°C (Sorvall RT 6000B Refrigerated b 
Centrifuge). 
'-' 0-
" ..r:: 
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d) After centrifugation, PBMCs remained at the interface of plasma and Ficoll. RBCs and other 
cell debris were precipitated at the bottom of the tube. The mononuclear cells were then 
collected from the top of the Ficolllayer carefully. 
e) The PBMCs were washed once in PBS at 953g for 10 minute at 20°C. 
Blood SlImple 
! 
Dilute with PBS (1 :1) 
! 
DIMe<! 
Blood 
Flcoll·Paque 
media 
Plasma 
Mononuclear 
cePs 
Ficotl.P3Que media 
Gmnulocytes 
Erythrocytes 
/ 
Upper !<lye< 
removed fOf 
monooucteilr 
t eNs collection 
Figure 2.2: Isolation of PBMC by density gradient centrifugation on Ficoll-Isopaque. 
t) The PBMCs were resuspended in 10 ml of PBS and cells were counted using a 
haemocytometer. 
g) After the second wash, the cells were resuspended in appropriate medium (appendix) to 
a required concentration to be used for further analysis. 
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2.5.2 Tritiated Thymidine eHT) T-cell Proliferation Assay 
Isolated PBMCs were incubated in 96-well tissue culture plates at 37°C in 5% CO2 for T-
cell proliferation. The T-cells sensitized with antigens proliferate in response to those 
antigens and secrete cytokines during the culture period. The extent of T-cell 
proliferation can be measured by incorporation of radiolabelled Tritiated Thymidine 
e HT) into the cells during cell divisions. More the incorporation of Thymidine in the T-
cell during proliferation indicates more the response to the antigens, which can be 
measured by liquid scintillation counter (LS 6500 Multipurpose Scintillation Counter, 
Beckman, USA). 
Table 2.1: Concentration of antigens used to stimulate cells 
Procedure 
I. Separated PBMCs from blood [section 2.6. 1] were resuspended in DMEM-ABS 
medium to a concentration of 107 cell slm I. 
2. I 00 ~Llwell cell suspension was added at triplicate in 96well cell culture plate (U 
bottom plate, cat# 163320, Nunclon, Denmark). 
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3. 100 ilL stimulants [PHA (lllg/ml); TT (51lg/ml)], diluted in DMEM-ABS, were 
added to the appropriate wells and 100 III DMEM-ABS medium to the negative 
control wells. 
4. The plate was incubated at 37°C plus 5% CO2 incubator for 2 days. 
5. After incubation, 100 ilL culture supernatant was aspirated from each well gently 
and store at -70°C. 
6. Then 100 ilL DMEM-ABS medium was added to each well. 
7. The plate was incubated at 37°C plus 5% CO2 incubator for 3 more days. 
8. After incubation, 25 III Tritium eH Thymidine) was added per well at a dilution 
of I :20 in DMEM-ABS medium. The Plate was incubated for at least 6 hours at 
37°C plus 5% CO2 incubator. 
9. The plate was harvested in automash. 
10. The paper was dried by I day at room temperature. 
I I. Then radioactivity of the dried paper was counted by Scintillation counter (LS 
6500-Multipurpose Scintillation Counter, Beckman, USA) after adding 2ml of 
scintillation fluid in each tube individually. 
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2.5.3 Determination of T-cell and naIve B-cells' percentage in 
Cord blood and peripheral blood by Flow cytometry (FACS) 
The bas is of a FACS analysis is a labeled (colored) suspensions of individual cells which 
passes a foc used laser-beam. Capillary forces cause the cell s to pass the flow-cell , where 
the labels are stimulated by the laser light. The emitted flo rescent light fTo m the 
flurophores, wh ich are coupled to the antibodies, and the scattered-light are detected 
separately. 
Table 2.2: Antibodies and their di lutions used in flow cytometry 
Antibody DUutioa Compllay 
anti-CD3-allophycocyanine I: 100 BD 
(anti-C03-APC), Cat#347543 
anti-CD4-peridinin chlorophyll protein \ :10 BD 
(anti-CD3-PerCP), Cat#347324 
anti-C08-fluorescein isothyocyanate 1:5 BD 
(anti-C08-FITC), Cat#340692 
anti-CD 19-phycoerythrin 1:5 BD 
(anti-CD 19-PE), Cat# 120457 
2.5.3.1 Procedure for staining lymphocyte surface antigens by antibody 
mixture 
I. 5x 104 PBMCs/well [collected by Ficoll procedure described in section 2.6.1] were 
taken on a V bottom-96 well plate (V96 MicroWell™ Plates, cat# 442587, Nunc) and 
resuspended in 200 1-11 of PBS. 
2. The cell suspension was centrifuged at 2000 rpm for 5 minutes at 4°C temperature. 
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3. The pooled FACS antibody mixture was prepared [anti-CD3 APC (1: 100), anti-CD4 
PreP (I: I 0), anti-CD8 FITC (I :5), anti-CD 19 PE (I :5)] (Table 2.2) 
4. Fifteen !-II of antibody mixture was added in each well. 
5. The plate was incubated at 4°C for 30 minutes. 
6. 100 !-II/well FACS buffer was added and the plate was centrifuged at 2000 rpm for 5 
minutes at 4°C temperature. 
7. The supernatant was discarded ant the cells were resuspended with 100 !-II/well cell fix 
(BD™ Stabilizing Fixation, BD Bioscience, San Jose, USA), ready for acquisition. 
2.5.3.2 Cell acquisition and analysis by Flow cytometry 
2.5.3.2.1 Cell Acquisition 
Cells were suspended with cell fix (BD TM Stabilizing Fixation, BD Bioscience, San Jose, 
USA) to stabilize the cells until acquisition. For acquisition of four-color fluorescence 
(perCP, FITC, PE, APC) tagged cells, acquisition was performed on a FACS Calibur 
instrument (BD, San Jose, CA) and CELLQUEST multipurpose software (version 3.3; 
Becton Dickinson) was used. Before data acquisition, instrument settings were checked 
to get a desired position of the cells according to the tagged fluorochrome. 
During cell acquisition, cells were recorded according to the antibody mixture. For every 
sample one tube was prepared and acquired for more than 20,000 cells. One negative 
control was used to compare with every stimulated sample. All samples were analyzed by 
setting appropriate forward and side-scatter gates targeting the round shaped lymphocytes 
population and thus the percentage of positive cells were estimated from gate. 
2.5.3.2.2 Gating strategies and analysis 
In] Gating principles: 
The data generated by flow-cytometer can be plotted in a single dimension, to produce 
a histogram, or in two-dimensional dot plots or even in three dimensions. The regions on 
these plots can be sequentially separated, based on fluorescence intensity, by creating a 
series of subset extractions, termed" gates. 
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It is an important principle of flow cytometry data analysis is to selectively visualize the 
cells of interest while eliminating results from unwanted particles e.g. dead cells and 
debris. This procedure is called gating. Cells have traditionally been gated according to 
physical characteristics. For instance, subcellular debris and clumps can be distinguished 
from single cells by size, estimated by forward scatter. Also, dead cells have lower 
forward scatter and higher side scatter than living cells. These same principles can be 
used to distinguish different cell populations. 
(b( Strategies used in the analysis: 
The Flow cytometry (FCM) data were analyzed with FLOWJO (version 8.5.3) software 
(Tree Star Inc.). Lymphocytes were gated via forward and side scatter properties (Fig 2.3 
A). Mononuclear cells were first gated based on forward and side scattering light, then 
different subpopulations were gated according to different staining patterns and results 
expressed as frequency of expression (Fig-2.3). T cells were identified based on their 
expression of the CD3+ cell surface marker (Fig 2.3 8). Among the CD3 cells, CD4+ and 
CD8+ cells were gated (Fig-2.3 C). In the same way, 8 cells were gated from 
lymphocytes based on their expression of CD 19+ marker (Fig 2.3 D) on lymphocyte 
population. 
33 
METHODS AND MATERIALS 
PCC ... 2 
""" 
.. 
, ~ .. 
FSCH: FSC-Helglrt FL4-H:C0 3 APe 
Fig: A Fig: B 
-
Fig: C Fl4-H:CD3 APC FL2-H: C019 PE Fig: D 
Figure 2.3: Demonstration of FACS Plot gating strategy following stimulation with 
antigens: A) Cells are separated according to FSC versus SSC. B) T-cells are separated 
by surface marker CD3+ T -cells C) CD4+ and CDS+ cells are separated from CD3+ cells 
and D) B cell as CD 19+ positive from total lymphocytes. 
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2.5.4 Enzyme Linked Immunosorbant Assay (ELlSA) 
Enzyme Linked Immunosorbant Assay (ELISA) is a qualitative and quantitative 
immunoassay in which antibodies or antigens are detected by the binding of an enzyme 
coupled to either anti-Ig antibody or antibody specific for the antigen. 
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Figure 2.4: Indirect ELISA to detect presence of antibody. (http://www.aI3malka.com) 
Plate is coated with specific antigen. Serum sample is added next. Antigen-specific 
antibodies will bind to the antigens. Secondary antibodies conjugated to an enzyme are 
added thereafter to allow its binding with the Fc portion of the bound antibodies. Finally a 
chromogenic substrate is added that will form color upon reacting with the enzyme. (Fig 
2.4) 
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2.5.4.1 Detection of JgA and IgG antibodies against B subunit 
of cholera toxin (CT) in plasma samples using GMl-ELlSA 
Plate coating: 
1. The antigen GM I (Sigma, cat#G-764I ) was diluted with Phosphate buffer saline 
(PBS) at concentration of 120nmol/ml. 
2. ELISA plates (Nunc F, Denmark) were coated with I 00 ~I/well of antigen 
suspension. 
3. The plates were kept at 4°C overnight. Following overnight incubation, the ELISA 
plates could be stored at 4°C up to 2 weeks for further use 
Blocking: 
4. The plates were washed thrice with PBS 
S. The plates were blocked with 0.1 % Bovine Serum Albumin in PBS (BSA-PBS); 
200 ~I/well. The plates were then incubated at 37°C for 30 minutes. 
Sample loading: 
6. The plates were washed thrice with PBS-O.OS% Tween and once with PBS only. 
7. The purified rCTB (O.S~g1ml in PBS) diluted in 0.1 % BSA-PBS were added, 
I OO~L per well and incubated at Room Temperature (RT) for 60 min at 37°C. 
8. The plates were washed 3 times with PBS - Tween (O.OS %) and once with PBS. 
9. The plasma samples (initial dilution 1:10 for IgA & 1:100 for IgG) diluted in 0.1% 
BSA-PBS containing O.OS% Tween were placed ISO ~I/well and were serially 
diluted three fold in microtiter plates with the final volume of I 00 ~I/well and 
10. The plates were incubated at Room Temperature (RT) for 90 minutes 
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Addition of Conjugate: 
II. The plates were washed thrice with PBS-0.05%Tween and once with PBS only. 
12. The conjugates (rabbit anti-human IgG conjugated to horse radish peroxidase 
(HRP), Jackson Immune Research Laboratories Inc.) were diluted (I: 1000) in 0.1 % 
BSA-PBS containing 0.05% Tween, and added to the wells (100 Ili /well). 
I. Anti-human 19A HRP (e.g. Jackson 309035011 , 1/1000) 
II. Anti-human IgG HRP (e.g. Jackson 309035006, 1/ 1000) 
13. The plates were incubated in room temperature for 90 minutes. 
Addition of Substrate plate developing: 
14. The plates were washed thrice with PBS-0.05%Tween and once with PBS only. 
15. The plates were developed by adding the substrate H20 2-OPO 
(Orthophenylenediamine, Sigma) , prepared by dissolving 10 mg OPO in 10 ml of 
0.1 M sodium citrate buffer ( pH 4.5), to which 30% H20 2 was added immediately 
before use, 100 IlVwe11. 
16. The reaction was stopped by adding 251lL H2S04 after 20 minutes. 
17. The optical density (0.0.) was measured at 492 nm by the ELISA reader in end 
point mode. 
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2.5.4.2 Detection of IgA and IgG antibodies against Heat 
Labile Toxin (LT) of Escherichia coli (E.coli) in Plasma 
samples using GMt-ELISA 
Plate coating: 
I. The antigen GMI (Sigma, cat#G-7641) was diluted with Phosphate buffer saline 
(PBS) at concentration of 120nmol/ml. 
2. ELISA plates (Nunc F, Denmark) were coated with I 00 ~I/well of antigen 
suspension. 
3. The plates were kept at 4°C overnight. Following overnight incubation, the 
ELISA plates could be stored at 4°C up to 2 weeks for further use 
Blocking: 
4. The plates were washed thrice with PBS 
S. The plates were blocked with 0.1 % Bovine Serum Albumin in PBS (BSA-PBS); 
200 ~I/well. The plates were then incubated at 37°C for 30 minutes. 
Sample loading: 
6. The plates were washed thrice with PBS-O.OS% Tween and once with PBS only. 
7. The purified LTB (O.S~g!ml in PBS) diluted in 0.1% BSA-PBS were added, 
I OO~L per well and incubated at Room Temperature (RT) for 60 min at 37°C. 
8. The plates were washed 3 times with PBS - Tween (O.OS %) and once with PBS. 
9. The plasma samples (initial dilution I: I 0 for IgA & I: I 00 for IgG) diluted in 
0.1 % BSA-PBS containing O.OS% Tween were placed ISO ~I/well and were 
serially diluted three fold in microtiter plates with the final volume of 100 
~I/well. 
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10. The plates were incubated at Room Temperature CRT) for 90 minutes 
Addition of Conjugate: 
II. The plates were washed thrice with PBS-0.05%Tween and once with PBS only. 
12. The conjugates (rabbit anti-human IgG and IgA, conjugated to horse radish 
peroxidase (HRP), Jackson Immune Research Laboratories Inc.) were diluted 
(I: I 000) in 0.1 % BSA-PBS containing 0.05% Tween and added to the wells (100 
Ili/well). 
I. Anti-human IgA HRP (e.g. Jackson 3090350 II, 1/ 1000) 
II. Anti-human IgG HRP (e.g. Jackson 309035006,111000) 
13. The plates were incubated in room temperature for 90 minutes. 
Addition of Substrate and plate developing: 
14. The plates were washed thrice with PBS-0.05%Tween and once with PBS only. 
15. The plates were developed by adding the substrate H20 2-0PO 
(Orthophenylenediamine, Sigma) , prepared by dissolving 10 mg OPO in 10 ml of 
0.1 M sodium citrate buffer ( pH 4.5), to which 30% H20 2 was added immediately 
before use, 100 Ill/well. 
16. After 20 minutes, the plates were read at 450 run in ELISA Reader (Ascent 
spectrophotometer) and again the optical density (0.0.) was measured at 492 nm 
by the ELISA reader (Ascent spectrophotometer) in end point mode immediately 
after stopping the reaction with 25 III of 1.0 M H2S04• 
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2.5.4.3 Detection of Tetanus Toxoid (TT) specific IgG 
antibodies by Enzyme Linked lmmunosorbent Assay (ELISA) 
Kit: SERJON ELISA classic Tetanus IgG 
Test Procedure: 
I. The samples were diluted (1+100) in dilution buffer solution. 
2. Diluted samples and ready-to-use control sera/standard sera were pipetted into the 
microtest wells (lOOfll). 
3. The plate was sealed and wrapped and incubated at 37°C for 60 minutes in moist 
chamber. 
4. The wells were washed four times with 300fll washing solution (I :30 dilution) per 
well. 
5. The ready-to-use conjugate solution (anti-human-lgG) was pipetted into the wells 
(IOOflllwell). 
6. The plate was sealed and wrapped and incubated at 37°C for 30 minutes in moist 
chamber. 
7. The wells were washed four times with 300fll washing solution (I :30 dilution) per 
well. 
8. The ready-to-use substrate solution (anti-human-lgG) was pipetted into the wells 
(IOOfll/well). 
9. The plate was sealed and wrapped and incubated at 37°C for 30 minutes in moist 
chamber. 
10. The ready-to-use stopping solution (anti-human-lgG) was pi petted into the wells 
(IOOfll/well) . 
II . The optical density (0.0.) was measured at 405 nm by the ELISA reader. 
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2.5.4.4 Detection of Measles Virus specific IgG antibody by 
Enzyme Linked Immunosorbent Assay (ELISA) 
Kit: Enzygnost® Anti-Measles ViruS/lgG 
Test Procedure: 
I. The colored sample buffer was prepared (800~1 total/strip) by adding 40~1 
colored solution in 800~1 non-colored sample buffer POD (diluent). 
2. 5~1 of serum sample was mixed well with colored sample buffer solution. 5~1 of 
anti-measles virus reference was also mixed well with colored sample buffer 
solution. 
3. The wells of the strips were filled by non-colored sample buffer POD; 200~I/well. 
4. The prediluted serum samples and anti-measles virus reference were added to the 
wells (20~l/well) and mixed well. 
5. The plate was then sealed and wrapped and incubated at 37°C for 60 minutes. 
6. The well content was aspirated and washed four times with diluted washing 
solution (2ml washing solution in 40ml dH20). 
7. 40~1 of conjugate (anti-human IgGIPOD) was added to 2ml of Conj ugate Buffer 
Microbial solution and shacked gently to mix well (per strip). 100~1 of this 
conjugate solution is then added to each well. 
8. The plate was then sealed and wrapped and incubated at 37°C for 60 minutes. 
9. The well content was aspirated and washed four times with diluted washing 
solution (2ml washing solution in 40ml dH20). 
I O. 200~1 of chromogen TMB was added to 2ml of Buffer Substrate TMB (per strip) 
and mixed. This solution was then kept in dark before use was I OO~I was added 
per well. 
I I. The plate was then sealed and wrapped and incubated at room temperature for 30 
minutes in dark. 
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12. The reaction was stopped by adding Stopping solution; 100flVweil. 
13. The optical density (0.0.) was measured at 450 nm by the ELISA reader. 
2.5.4.5 Determination of fecal antibody, immunoglobulin A 
(lgA) 
Plate coating: 
I. The antigen Affinipure Goat anti-human IgG ((Fab 'h (Jackson Immune Research 
Laboratories Inc. Cat# 109-005-097) was diluted with Phosphate buffer saline (PBS) 
at concentration of 1.0 flg/ml. 
2. ELI SA plates (Nunc F. Denmark) were coated with 100 fli /well of antigen 
suspension. 
3. The plates were kept at 4°C overnight. Following overnight incubation, the 
ELISA plates could be stored at 4°C up to 2 weeks for further use. 
Blocking: 
4. The plates were washed thrice with PBS. 
5. The plates were blocked with 0.1% Bovine Serum Albumin in PBS (BSA-PBS); 
200 fli/weli. The plates were then incubated at 37°C for 30 minutes. 
Sample loading: 
6. The plates were washed thrice with PBS-0.05% Tween and once with PBS only. 
7. The fecal extract samples (initial dilution I :500) diluted in 0.1 % BSA-PBS 
containing 0.05% Tween were placed 150 fli/well and were serially diluted three 
fold in microtiter plates with the final volume of 100 fli/weli. 
8. The plates were incubated at Room Temperature (RT) for 90 minutes. 
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Addition of Conjugate: 
9. The plates were washed thrice with PBS-0.05%Tween and once with PBS only. 
10. The HRP conjugated goat anti-human IgA (Jackson Immune Research Laboratories 
Inc. Cat# 109-035-011) were diluted (1 :3000) in 0.1 % BSA-PBS Tween (0.05%) and. 
added 100 !ll 1 well. 
11. The plates were incubated in room tempe:-~t~:-e fo !" 60 ~!~~te~ . 
Addition of Substrate and plate developing: 
12 .. The platcs wcre washed thrice with PBS-0.05%Tween and once with PBS. 
13. The plates were developed by adding the substrate H20 2-0PD 
(Orthophenylenediamine, Sigma), prepared by dissolving 10 mg OPD in 10 ml of 
O.lM sodium citrate buffer (pH 4.5), to which 30% H20 2 was added immediately 
before use, IOO!lllwell. 
14. The optical density (O.D) was measured after 20 min at 450 om in Multiskan 
Ascent ELISA reader. 
IS. Endpoint titers were determined as the reciprocal of the interpolated dilution of the 
test samples giving an absorbance of 0.4 above the background absorbance. 
TotallgA Calculation: 
After dilution of breast milk pool conc. oflgA is 2.0 !lg/ml. So the titer we get in ELISA is 
equivalent to this conc. For example pool titer is 6750 and sample titer is 3524. 
So, 6750 ; 2 !lg/ml 
3524 ; (3524*2)/6750; 1.044 !lg/ml 
So, conc. of 1 :50 times diluted stool extract is 1.044!lg/rnl 
Hence, conc. of undiluted stool extract is 50*1 .044=52.2 !lg/ml 
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2.5.4.6 Detection of Fecal IgA antibodies against Heat Labile 
Toxin (LT) of Escherichia coli (E.colt) by GMl-ELISA 
Plate coating: 
I. The antigen GMI (Sigma, cat#G-7641) was diluted with Phosphate buffer saline 
(PBS) at concentration of 120nrn01lml. 
2. ELISA plates (Nunc F, Denmark) were coated with 100 ~I/well of antigen 
suspension. 
3. The plates were kept at 4°C overnight. Following overnight incubation, the 
ELISA plates could be stored at 4°C up to 2 weeks for further use 
Blocking: 
4. The plates were washed thrice with PBS 
5. The plates were blocked with 0.1 % Bovine Serum Albumin in PBS (BSA-PBS); 
200 ~l/well. The plates were then incubated at 37°C for 30 minutes. 
Sample loading: 
6. The plates were washed thrice with PBS-0.05% Tween and once with PBS only. 
7. The purified LTB (0.5~g/ml in PBS) diluted in 0.1 % BSA-PBS were added, 
lOO~L per well and incubated at Room Temperature (RT) for 60 min at 37°C. 
8. The plates were washed 3 times with PBS - Tween (0.05 %) and once with PBS. 
9. The undiluted (neat) fecal extract samples were placed ISO ~l/well and were 
serially diluted three fold in microliter plates with the final volume of 100 
~1Iwell. 
10. The plates were incubated at Room Temperature (RT) for 90 minutes. 
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Addition o/Conjugate: 
II. The plates were washed thrice with PBS-0.05%Tween and once with PBS only. 
12. The conjugate (rabbit anti-human IgA conjugated to horse radish peroxidase 
(HRP), Jackson Immune Research Laboratories Inc.) were diluted (I: 1000) in 
0.1 % BSA-PBS containing 0.05% Tween, and added to the wells (100 fll/well). 
I. Anti-human 19A HRP (e.g. Jackson 309035011,1 / 1000) 
13. The plates were incubated in room temperature for 90 minutes. 
Addition 0/ Substrate and plate developing: 
14. The plates were washed thrice with PBS-0.05%Tween and once with PBS only. 
15. The plates were developed by adding the substrate H202-0PO 
(Orthophenylenediamine, Sigma), prepared by dissolving 10 mg OPO in 10 ml of 
0.1 M sodium citrate buffer ( pH 4.5), to which 30% H20 2 was added immediately 
before use, 100 fll /well. 
16. The reaction was stopped by adding 25fll H2S04 after 20 minutes. 
17. The optical density (0.0.) was measured at 492 nm by the ELISA reader in end 
point mode. 
2.6.5 Vibriocidal Antibody Assay 
Vibrio choJerae is exceedingly susceptible to the bactericidal effect of 0 antibody in the 
presence of complements. Vibriocidal tests, in principle, depend on exposure of dilutions 
of plasma to a carefully standardized constant inoculum of Vibrio choJerae in the 
presence of excess guinea pig complement, an incubation period to permit killing of 
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bacteria, and subculture of the dilutions of plasma and appropriate controls on agar or in 
broth. 
Vibriocidal antibody assays were performed using guinea pig complement and with V. 
cholerae 01 Ogawa (X-25049) and V. cholerae 01 Inaba (strain 19479 EI Tor) as the 
target organisms. Vibrioeidal titer was defined as the reciprocal of the highest dilution 
resulting in >50% reduction of the optical density when compared to that of control wells 
without serum. Individuals showing a "~:4-fold increase in vibriocidal responses one or 
three weeks post infection (if any) or vaccination were considered responders. 
Procedure 
a) Vibrio cholerae 01 Ogawa (X-25049), Vibrio cholerae 01 lnaba (strain 19479 EI Tor) were 
cultured overnight on blood agar plates at 37°C. 
b) A loopful of bacteria from the plates was inoculated in 15 ml Bovine-Heart Infusion (BHI) 
medium in a conical flask with cotton plug. This was incubated on a shaker at 37°C for 3-4 
hours. 
c) The culture was centrifuged at 3000rpm for 10 minutes and the supernatant was thrown 
away. The sediment was resuspended in sterile saline. 
d) This was again centrifuged for another 8-10 minutes. The pellet was resuspended in sterile 
saline. 
e) Bacterial concentration was adjusted optical density by spectrophotometer at 600 nm. 
For V. cholerae 0 I (X25049 and 19479) -+ adjusted at 0.3 
f) Heat-inactivated (56° C, 30 minutes) sera was diluted 2-fold in sterile saline in flat-bottom 
microtiter plates (Nunc, F) as follows: 
o 25 f11 of cold saline was dispensed in all wells except column #2. 
N 
o 45 f11 of cold saline and 5 f11 of test sera were dispensed in column #2. The sera was serially i-: 
'-' ..., 
diluted (initial dilution I: I 0) 2-fold by using a multi-channel dispenser. The dilution was 0-
" 
accomplished by mixing the solution in column #2, aspirating 25 f11 and dispensing and 6 
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mixing the sample in column #3 and so on, till column # 12 (this equals to I: I 0240). The 
last 25 fll was discarded from the last well on each row. The plates were kept at 4°C (on ice) 
until used. 
g) The indicator (bacteria-complement [Guinea pig Sera, SigmaJ-saline mixture) was prepared. 
The composition for each plates is as follows: 
Still. SterIle s.Hae COiipli.'-
V. cholerae 01 (X25049 and 19479) 2.55 ml 150 fll 300 fll 
I 
h) The indicator was used immediately after preparation. 
i) 25 fll of the indicator was added to all wells except wells in row A, B, C and D in column 
#1. The plate was incubated on a shaker at 37°C for I hour (50 revolutions Imin) . 
j) After incubation, 150 fll BHl broth/well were added. The plates were again incubated for 
another 3-4 hours at 37°C without shaking. 
k) The plates visually and spectrophotometrically. The absorbance for control wells should 
reach 0.20 to 0.28 at 595 nm. 
I) Vibriocidal antibody titer is defined as the reciprocal of the highest serum dilutions resulting 
in greater than 50% 00 reduction when compared to control wells without serum. 
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2.7 Statistical Analysis of the Data 
Data analyses were carried out using the Microsoft Excel and GraphPad Prism 5.02. 
Following acquisition by the flow cytometer, the acquired cells were analyzed by using 
the multipurpose analysis software Flowjo (Tree Star, Inc., version 8.5.3). It was used for 
making different gating and plots. GraphPad Prism 5.02 was used for graph preparation 
and measurement of significance level as comparison between the values of different 
experiments were then analyzed by, unpaired t-test, Mann-Whitney Rank Sum test to 
evaluate statistical differences between and/or within study groups, where appropriate. A 
P-value of s O.05 was the criterion for a statistically significant difference. Data were 
expressed as median, arithmetic, geometric mean and standard error of mean (±SEM). 
-tS 
CHAPTER 3 
RESULTS 
RESULTS 
3.1 Baseline data of study children 
A total of fifty children were enrolled in this study. Forty children were taken from the 
Mirpur area, and ten cord blood specimens were collected from the same area and 
considered as the neonate specimen. All the subjects are children of between 6 months to 
24 months of age and newborn, were divided into five groups depending upon age. The 
children of different groups were comparable with respect to their age and gender (Table 
3.1 ). 
Table 3.1: Baseline data of study participants 
Study Participants 
Characteristics Groupl Group II Group III GrouplV Group V 
Total enrollment 10 10 10 10 10 
Age (month) 0 6 12 18 24 
(Cord blood 
specimen) 
Sex Female 5 7 4 3 7 
Male 4 3 6 7 3 
3.2 Comparison of T cell proliferation of study participants 
The T cell response of infants of all groups to tetanus toxoid (TT) and phytohemaglutinin 
(PHA) was measured by T cell proliferation Assay. Proliferation was assessed by 
determination of radiolabelled tritiated thymidine eHT) incorporation into the T cells 
after 5 days incubation of in-vitro cultures and expressed by comparison with cells 
incubated in absence of antigen (unstimulated) as stimulation index (Sl). 
RESULTS 
In case of T cell response against Tetanus toxoid (IT) antigen, gradual increase of 
response was seen among the groups. Although newborns showed significantly lower 
response when compared with 6 months (P= 0.013), 12 months (P =0.003), 18 months (P 
=0.0 I), and 24 months old subjects (P <0.000 I) (Fig-3.1). 
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Figure 3.1: Comparison of T cell responses to tetanus toxoid (TT) antigen for infants 
of different ages. The statistical analysis was done by Mann-Whitney Rank Sum Test for 
comparison of two groups. The results were considered significant when P :::: 0.05 . The 
bars represent the mean values whereas the error bars represented the SEM. 
However, T cell response of the study children to phytohemaglutinin (PHA), 6 months 
infants showed lowest response where 18 months old children showed the highest 
response among the groups. Again, 24 months children response was significantly higher 
than 6 months (P= 0.02) (Fig-3 .2). 
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Figure 3.2: Comparison of T cell responses to phytohemaglutinin (PHA) antigen for 
infants of different ages. The statistical analysis was done by Mann-Whitney Rank Sum 
Test for comparison of two groups. The results were considered significant when P :5 
0.05. The bars represent the mean values whereas the error bars represented the SEM. 
Intra-group analysis for change in T cell response to unstimulated (US), tetanus toxoid 
(TT) and phytohemaglutinin (PHA) showed gradual increase in response to these 
antigens respectively in all groups of age. 
In newborn, PHA response was significantly higher than TT (P= 0.003) where, US 
response to PHA was 30 fold lower when median was consider (Fig-3.3 A). T cell 
response of 6 months old infants to phytohemaglutinin (PHA) was 13 and 7 fold higher 
than unstimulated (US) and tetanus toxoid (TT) respectively (Fig-3.3 B). 
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Figure 3.3: Intra-group Comparison of T cell responses to unstimulated (US), 
tetanus toxoid (TT) and pbytobemaglutinin (PHA).The statistical analysis was done 
by Mann-Whitney Rank Sum Test for comparison of two groups. The results were 
considered significant when P :5 0.05. The bars represent the mean values whereas the 
error bars represented the SEM. 
Rl:SULTS 
Children of 12 months of age showed significantly lower T cell response to US than TT 
and PHA which were 12 and 35 folds respectively, where PHA response were higher 
than TT (P= 0.02) (Fig-3.3 C). 
However, phytohemaglutinin (PHA) response of T cell was found to be significantly 
elevated, around 30 folds than in unstimulated (US) and TT (P= 0.02) in 18 months 
children(Fig-3.3 D). Similar response was found in case of24 months old children, where 
PHA response were significantly higher than TT (P= 0.004) (Fig 3.3 E). 
3.3 Distribution of T-cell and B-cell specific Surface proteins, 
Clusters of differentiation (CD) markers 
The distribution of T-cell and B-cell specific surface proteins clusters of differentiation 
(CD) markers on lymphocytes of cord blood and peripheral blood was measured by Flow 
cytometry (FACS). 
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Figure 3.4: The Distribution of lymphocytes in infants of different ages. The 
statistical analysis was done by Mann-Whitney Rank Sum Test for comparison of two 
groups. The results were considered significant when P :S 0.05. The bars represent the 
median values whereas the error bars represented the SEM. 
RESULTS 
Total lymphocyte population was found to be higher in newborns, 6 months and 24 
months children than 12 and 18 months old children. 
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Figure 3.5: The Distribution T-cell specific surface proteins, clusters of 
differentiation (CD) markers on lymphocytes and ratio of Helper and cytotoxic T 
cells. The statistical analysis was done by Mann-Whitney Rank Sum Test for comparison 
of two groups. The results were considered significant when P was ~ 0.05. The bars 
represent the median values whereas the error bars represented the SEM. 
RESULTS 
Total T cell (COl,) population was also found to be significantly lower in newborns than 
6 months (P< 0.000 1),12 months (P< 0.000 1), 18 months (P= 0.00 I) and 24 months (P< 
0.000 I ) old children (Fig- 3.5 A.). 
Among the T cells, percentage of T helper cells (CD3+ CD4) were similar in 6 months, 
12 months 18 months and 24 months old children although it was significantly higher in 
newborns than 24 month children (P= 0.049) (Fig- 3.5 B.). 
Distribution of cytotoxic T cells (CD3+ CD8) was found not to be significantly different 
in all the age groups. (Fig- 3.5 C). 
However, age-dependent decrease of helper and cytotoxic T cells ratio (CD4+/CD8) was 
observed among the study chlidren. (Fig-3.5 D). 
P<O.OOOl 
f'z0.001 
P<O.OOOl 
30 P-0.OOO2 , 
• • 
.!! A.' 
" Qi • • .' • • u 20 • • + • •• en 
••• 
--.:-;:-
.' • • .... 
C '., •• 0 •• • 
.... 10 
• • 0 
• • ~ 
--.... 
0 
0 • 
v'b '0+ ...... + b+ 
... 
,,+ 
'); 
Age 
Figure 3.6: The Distribution 8-cell specific surface proteins, clusters of 
differentiation (CD) marker on lymphocytes. The statistical analysis was done by 
Mann-Whitney Rank Sum Test for comparison of two groups. The results were 
considered significant when P was ~ 0.05. The bars represent the median values whereas 
the error bars represented the SEM. 
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RESULTS 
However, percentage ofB cell (CD 19+ cells) population was notably lower in newborns 
than 6 months (P= 0.0002), 12 months (P< 0.000 I), 18 months (P= 0.00 I) and 24 months 
(P< 0.000 I) old children (Fig- 3.6). 
3.4 Cholera toxin (CT) specific Plasma Immunoglobulins 
The level of plasma response to cholera toxin (CT) of Vibrio cholerae specific 
immunoglobulins (lgG and IgA) was quantitatively determined by the GMI-Enzyme 
linked immunosorbent assay (ELISA). 
3.4.1 Plasma response for cholera toxin (CT) specific immunoglobulin G (IgG) 
The CT-specific plasma IgG response was similar in infants of6 months and 12 months. 
Plasma IgG response to CT was significantly lower in newborns than 18 months (P= 
0.001) and 24 months (P< 0.0001) where 24 months children had significantly elevated 
level ofCT-specific IgG than 6 months old infants (P= 0.03) (Fig-3.7 A.). 
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Figure 3.7: Plasma response to CT -specific IgG and JgA. The statistical analysis was 
done by Mann-Whitney Rank Sum Test for comparison of two groups. The results were 
considered significant when P S 0.05. The bars represent the mean values whereas the 
error bars represented the SEM. 
3.4.2 Level of Plasma response for cholera toxin (CT) specific immunoglobulin A 
(lgA) 
Again , CT-specific plasma IgA response was found to be significantly lower in newborns 
than in 6 months (P= 0.0003), 12 months (P= 0.000 I), 18 months (P= 0.000 I), and 24 
months (P= 0.000 I). However, infants of 6 months showed significantly lower IgA 
response than 12 months (P= 0.02), 18 months (P= 0.03), and 24 months (P= 0.007). 
(Fig-3.7 B). 
RESULTS 
3.5 Level of Heat Labile toxin (L T) of Escherichia coli specific 
plasma immunoglobulins 
The plasma response to Heat Labile toxin (L T) specific immunoglobulins (lgG and IgA) 
was quantitatively determined by the GM I-Enzyme linked immunosorbent assay 
(ELISA). 
3.5.1 Level of Plasma response for Heat Labile toxin (LT) specific immunoglobulin 
G (IgG) 
The LT-specific plasma IgG response was found to be gradually increased with age of the 
subject infants. Plasma IgG response to L T was significantly lower in newborns than in 6 
months (p= 0.02), 12 months (P= 0.0005), 18 months (P= 0.0003) and 24 months (P< 
0.000 I) children (P= 0.03) (Fig-3.8 A.). 
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Figure 3.8: Plasma response to L T -specific JgG and JgA. The statistical analysis was 
done by Mann-Whitney Rank Sum Test for comparison of two groups. The results were 
considered significant when P :5 0.05. The bars represent the mean values whereas the 
error bars represented the SEM. 
RESULTS 
3.5.2 Level of Plasma response for Heat Labile toxin (LT) specific immunoglobulin 
A (lgA) 
However, L T-specific plasma IgA response was found to be significantly lower in 
newborns than in 6 months (P= 0.0001), 12 months (P= 0.0001), 18 months (P= 0.0001), 
and 24 months (P= 0.0001). Although, 6 months infants showed notably lower IgA 
response than 24 months (P= 0.03). Moreover, 18 months old children had elevated IgA 
level when compared with 6 months (P= 0.03) and 12 months (P= 0.03) (Fig-3 .8 8.). 
3.6 Vaccine specific Plasma Immunoglobulin G (IgG) response 
to Tetanus toxoid (TT) 
Tetanus toxoid (IT) specific plasma immunoglobulin G (IgG) response was measured by 
commercially available Enzyme linked immunosorbent assay (ELISA) system, SERJON 
ELISA classic Tetanus IgG kit 
TT-specific IgG level was found to be elevated in newborns among the infants which 
gradually decreased till 18 month of age. Newborn IgG level was appreciably higher than 
6 months (P= 0.04), 12 months (P= 0.02), 18 months (P= 0.007) and 24 months (P= 
0.02) old children. (Fig-3.9). 
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Figure 3.9: Vaccine specific plasma response to TT-specific immunoglobulin G 
(IgG). The statistical analysis was done by Mann-Whitney Rank Sum Test for 
comparison of two groups. The results were considered significant when P S 0.05. The 
bars represent the mean values whereas the error bars represented the SEM. 
3.7 Vaccine specific Plasma Immunoglobulin G (lgG) response 
to Measles virus 
Measles virus specific IgG was determined by commercially available Enzyme linked 
immunosorbent assay (ELISA) system, Enzygnost® Anti-Measles Virus/lgG. 
Plasma anti-measles IgG level was significantly elevated in newborns than 6 months (P= 
0.001), 12 months (P= 0.03), 18 months (P= 0.009) and 24 months (P= 0.015) old 
children. Moreover, 6 months old infants had notably lower level of IgG than 18 months 
(P= 0.04) (Fig-3.1 0) . 
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Figure 3.10: Vaccine specific plasma response for Measles virus specific 
immunoglobulin G (IgG). The statistical analysis was done by Mann-Whitney Rank 
Sum Test for comparison of two groups. The results were considered significant when P 
:S 0.05. The bars represent the mean values whereas the error bars represented the SEM. 
3.8 Vibriocidal Antibody Responses 
Vibriocidal antibody response is an indication of Vibrio cholerae killing activity of 
plasma. It was measured by Vibriocidal antibody assay. The assay was carried out for 
Ogawa (Strain X-25049) and Inaba (Strain-19479) serotypes of Vibrio cholerae 0 I. 
The vibriocidal plasma response was expressed as antibody titer. For Ogawa serotype, 
there was no significant change of response was found in all age groups, (Fig-3.ll A.). 
Similarly, for lnaba the antibody titer near the base line in all age groups was observed 
(Fig-3.11 B.). 
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Figure 3.11: Vibriocidal antibody response in plasma A. Ogawa, B. Inaba The 
statistical analysis was done by Mann-Whitney Rank Sum Test for comparison of two 
groups. The results were considered significant when P S 0.05. The bars represent the 
median values whereas the error bars represented the SEM. 
3.9 Fecal antibody, Immunoglobulin A (IgA) Profile 
Fecal antibody, immunoglobulin A (lgA) of the study participants (except newborns) was 
measured by Enzyme linked immunosorbent assay (ELISA). 
3.9.1 Fecal total [gA Content 
Fecal total IgA content was found to be differing insignificantly. However, among the 
infants, 6 months showed lowest IgA content but highest in 12 months old a children, 
which was decreased gradually with the increasing age up to 24 months (Fig-3.12 A.). 
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Figure 3.12: Fecal total IgA and L T -specific IgA. The statistical analysis was done by 
Mann-Whitney Rank Sum Test for comparison of two groups. The results were 
considered significant when P ::; 0.05. The bars represent the mean values whereas the 
error bars represented the SEM. 
3.9.2 Heat labile toxin (LT) of Escherichia coli specific fecal immunoglobulin A 
(lgA) 
The L T -specific fecal IgA response was found to be low at 6, 18 and 24 months old 
children , although it was significantly elevated at 12 months than 24 months children 
(P= 0.021) (Fig-3.12 8.). 
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Human neonates are highly susceptible to infections by a wide range of bacteria, viruses, 
protozoa, and fungi {Marodi, 2006 #II} and remain as the most common infectious 
agents responsible for death in early life. The role of the immune system has recently been 
reported to be specifically adapted rather than immature {Wood, 2011 #291} at birth is to 
protect neonates from those pathogens during postnatal life {Trivedi, 1997 # 119}. 
Recognition of the high burden of disease in early life and advances in the understanding 
of neonatal immunology has resulted in renewed interest in the study of the functional 
maturation of neonates. In view of these observations, the present study was undertaken 
to evaluate the development of immune response of healthy infants of different ages 
between birth to two years. 
The knowledge of the kinetics of the changes occurring In postnatal period, and 
associated qualitative/ quantitative changes in individual cellular functions, is 
exceedingly sparse {Holt, 2000 #83}. In our present study, the postnatal immune 
functions development in human unti I 2 years was compared with cord blood that 
represents the neonatal blood. 
We analyzed the immune function of cord blood mononuclear cells (CBMC) in 
comparison to peripheral blood mononuclear cells (PBMC) of infants in different ages. 
The inability of neonates to respond to antigen stimulation in vitro that has been proposed 
by Lewis D.B. and Wilson C.B may be due to less antigen-experience and exposure 
{Lewis DB, 1995 #120}. However, T cell hypo responsiveness in neonates reported by 
Pirenne H.Y. et al reflects an inherent functional immaturity of T cells {Pirenne, 1992 
# 128}. 
In our study, poor T cell proliferative responses to mitogen, phytohemagglutinin (PHA) 
was found in newborns and young infants of 6 months and 12 month than the elderly 
children of 18 month and 24 months (P= 0.02) which presumably could be due to 
evolution of antigen primed T cells from naIve neonatal T cells and their increase in 
number with age. 
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Further, we evaluated T cell proliferative responses induced by a vaccine antigen, tetanus 
toxoid (TT), which is currently in use at different stages of immunological maturation 
(from birth to 14 weeks of age). Age dependent increase in T cell response to tetanus 
toxoid (TT) was observed in our study, which suggests the age-dependent progressive 
maturation ofT-ceil responses in infants. 
However, delayed or less responsiveness to antigen due to immaturity of neonatal T cell 
was also reported by Harris, D. T et 01 in another study conducted in North America 
{Harris, 1992 #173}. 
In this study, the T and B cell specific cell surface protein, cluster of differentiation (CD) 
on lymphocytes were analyzed immediately upon isolation and antibody staining of 
CBMC and PBMC by flow cytometry (FACS). We found that cord blood contained 
lower numbers of CD3+, CD4+ and CDS+ cells than peripheral blood of study participant 
infants. More importantly, we also observed that newborn T cells expressed the CD3+ 
antigen at lower level than 6 months (P< 0.000 I), 12 months (P< 0.000 I), IS months (P= 
0.001) and 24 months (P< 0.0001) old children T cells and may represent maturational 
intermediates that mayor may not be fully functional. In addition, gradual fall in 
CD4+/CDS+ ratio following increase of age was found in our study, which demonstrates 
maturation of cytotoxic capacity of infant T-cell over age. 
However, in another neonatal study, Chirico G. et 01 showed similar age dependent 
maturation of T cell through increase in cytotoxic function of T cell and decrease in ratio 
ofT helper and cytotoxic Tcells (CD4+/CDS) upon age {Chirico, 2005 # 163}. 
Percentage of B lymphocytes (CD 19) was also found significantly low in cord blood 
than in peripheral blood of children at 6 months (P=0.0002), 12 months (P< 0.000 I), IS 
months (P= 0.00 I) and 24 months of age (P< 0.000 I). The presence of B cell specific CD 
antigens other than CD J 9+ like CD5+, CD20+, CD21 + and CD22+ in newborns is 
perhaps a reason for its low percentage of CD 19+ than infants blood as presence of high 
percentage of CD5+CD 19+ B cells was reported by Randolph D A in 2005 {Randolph, 
2005 #2 11}. 
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In this study, we have analyzed the systemic immune responses of the IgG and IgA 
antibodies against cholera toxin (Cn of V. cholerae. The IgG ELISA method was found 
to be particularly suitable for seroepidemiological studies of cholera {Levine, 1981 
#277}. Radically elevated level of CT-specific IgG response was seen in infants of other 
age groups when compared with newborns. In contrast, the 24 month aged children had 
significantly elevated levels oflgG than the 6 months old infants (P= 0.03). Besides, CT-
specific plasma IgA response was found to be significantly lower in newborns than in 6 
months (P= 0.0003), 12 months (P= 0.000 I), 18 months (P= 0.000 I), and 24 months (P= 
0.000 I) old children. However, 6 months old infants showed much lower IgA response 
than 12 months (P= 0.02), 18 months (P= 0.029), and 24 months (Fig 3.7) old ones, 
possibly due to lack of placental transfer ofmaternallgA to fetus during pregnancy. 
Bangladesh is an endemic country for enterotoxigenic Escherichia coli (ETEC) infection, 
Significant difference in L T-specific IgA responses (Fig 3.8) was observed among the 
group of infants than 19G responses in our study, which may be due to previously 
explained placental transfer of IgG rather IgA during gestational life. 
In our study, similar antibody responses were observed with the B subunits ofLT and CT 
using GM I ELISA. Since L T has antigenic determinants (about 80% sequence homology 
{Moseley, 1980 #274} {Dallas, 1979 #275}) in common with the B subunits ofCT,these 
could share several properties at the molecular level like common colonization 
mechanism {Clements, 1979 #26 1 }{Clements, 1980 #262}{ Field , 1979 #263 }{Geary, 
1982 #264}{ Kantor, 1975 #267}{Clements, 1978 #265}{Donta, 1974 #272}{Honda, 
1981 #27 1}{Holmgren, 1973 #270}{Gyles, 1974 #269}{ Klipstein, 1977 #268} . Most 
likely due to the presence of cross-reactive antibodies, our study has found similar 
antibody responses with the B subunits of L T and CT. 
Vibriocidal antibody assay is a sensitive tool for measuring vibriocidal antibodies that are 
the best studied and reliable surrogate markers of protective immunity to cholera 
{Finkelstein, 1962 #248} {Qadri, 1995 #257} . 
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In current study, vibriocidal plasma antibody response was measured against two 
common serotypes of V choferae, Ogawa (X-25049) and Inaba (Strain-I 9479). We 
found plasma vibriocidal antibody response expressed as vibriocidal titer, did not differ 
significantly in infants of all age groups for both the target serotypes of V choferae 01 
organisms. 
A recently conducted study on both children and adult cholera patients in our country 
also confirmed the fact that, infants have the lowest baseline vibriocidal antibody levels 
compared to children and adults, presumably reflecting the previous exposure to V 
choferae infections with growing age, as living in an area of cholera endemicity {Leung, 
2011 #283}. 
A standard measure of successful immunization is the development of antigen specific 
humoral immunity {Ochsenbein AF, 2000 #245}. In our study, vaccine specific immune 
response to tetanus toxoid (IT) was determined by quantification of TT specific IgG with 
a commercially available sensitive and specific enzyme-linked immunosorbent assay 
(ELISA) system. Gradual decline of IgG from newborns to 18 months of age was seen 
probably due to the 2 dose vaccination {WHO, 2010 #64} {WHO, 2011 #235} {WHO, 
1996 #281} to mother during pregnancy and 3 dose vaccination to neonate during early 
infancy {WHO, 2011 #235} . 
To evaluate vaccine specific immune response to measles, our study found high levels of 
cord blood-measles virus IgG responses than in infants of 6 months of age. This can be 
explained by the presence of high titer of maternal antibodies in newborns which have 
influence on the response. In contrast, responses were seen consistent in the higher age 
groups (Fig 3. 10) upon vaccination at around 9 months {WHO, 1996 #281} when 
presence of maternal antibodies is very less of no longer can be detected. 
Earlier, Albrecht, P el af described the presence of maternal antibody as a possible reason 
of measles vaccine failure in early infancy and presence of high anti-measles virus 
antibody titer {Albrecht, 1977 #42} {Siegrist, 1998 #39} {Siegrist, 1998 #20}. 
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The main protective immunoglobulin at intestinal mucosal surfaces is /gA. The level of 
protective fecal \gA was measured in this study to assess the development of infant 
intestine. Among the study infants, 12 months old showed maximum IgA content 
possibly be due to influence of breast milk derived IgA as cord blood donor neonates 
were excluded from this part of the study because of unavailability of collection of fecal 
sample at the moment of blood collection. 
It is becoming increasingly clear from recent studies that the seeds for expression of a 
variety of immunologically mediated diseases in adulthood are sown during infancy i.e. 
early postnatal life. During this period, the immune system is fine-tuning a variety of key 
functions, in the face of direct stimulation from environmental signals not previously 
encountered during fetal life, and the response patterns " learned " during this period 
persist into adult life. 
The present study was conducted to observe development of infant immune response in 
different time periods from various aspects which may in future be helpful for analyses of 
mechanisms that underlie differential immune responses in newborns and infants so that 
prevention and treatment of neonatal infections can more safely be targeted to address 
UN Millennium Development Goal 4 on reducing childhood mortality. These baseline 
results will also help in understanding the reason children in Bangladesh and in other 
developing countries show differential responses to vaccines and infections compared to 
those living in industrialized settings. Such studies need to be undertaken. 
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APPENDICES 
Laboratory Apparatus 
I. Eppendorf tubes and micropipette tips were taken from Eppendorfi' and Sigma, 
and were sterilized by autocIaving at 12 1°C for 20 minutes. 
2. Petridishes used in the experiments were provided by either Sterilin or Gibco. 
Screw capped tubes and other glass wares were taken from Pyrex® Labware, 
USA. 
3. Plastic tubes and pipettes were of Falcon®; both were the brands of Becton, 
Dickinson and Company, USA. 
4. 96F Microwell low affinity ELISA plates and 96U T-cell culture plates were 
obtained from Nunc TN, Sweden. 
5. Micropipettes were from Thermo Labsystems. 
6. Multi-channel dispensers (Lab Systems, USA). 
7. Mini scale centrifugations were carried out in eppendorfi' Centrifuge 5417R, 
large-scale centrifugation were carried out in a Sorvall® RT 6000B Refrigerated 
Centrifuge. ELISA and vibriocidal reading were taken using ASCENT 
Multiskan® reader. T-cell proliferation was measured by LS6500 Multipurpose 
Scintillation Counter, Becton, USA. Flow cytometry is done by FACS Cali bur 
instrument, BD, USA . 
8. Heparin-coated sterile vacutainer tubes (Becton Dickinson, Ruther-ford, NJ). 
I. BSA (Bovine Serum Albumin), Gibco BRL- 16140-071. 
2. Ficoll-Isopaque, GE Healthcare, Uppsala, Sweden. 
3. Rabbit anti-human immunoglobulins, Affinipure (goat-antihuman IgG), horse 
radish peroxidase (HRP), Jackson Immuno Research, West Grove, P. A., USA 
4. H20 2 (Hydrogen Peroxide), Fisher Scientific, H-325. 
5. Orthophenyline diamine (OPO) Sigma- 7786-30-3. 
6. Brain-heart infusion Media, Becto™, BO, USA. 
7. Guinea pig complement sera, Sigma. 
II 
BUFFERS AND SUBSTRATE SOLUTIONS 
Preparation of phosphate bulTer saline (PBS) (Vacutainer System; Becton 
Dickinson, Rutherford, NJ) (pH 7.2) 
NaCI (Fischer Scientific, Pittsburgh, PA, USA) 80.00 g 
Na2HP04 II.SO g 
KH2P04 2.00 g 
KCL (Fischer Scientific, Pittsburgh, PA, USA) 2.00g 
Deionized water 1000.0 ml 
The concentrated solution (I OxPBS) was diluted ten times and was used as working 
so lution. 
Preparation of 0.1 % BSA in PBS (500 ml) 
Phosphate Buffer Saline (PBS) SOOml 
Bovine Serum Albumin (BSA) O.S g 
Preparation of 0.1% BSA in PBS-Tween (500 ml) 
Phosphate Buffer Saline (PBS) SOOml 
Bovine Serum Albumin (BSA) O.S g 
Tween 2S0 III 
III 
29.40 gm 
Deionized water 1000.0 ml 
Preparation of Ortbopbenylene diamine - HlOl substrate (10 ml) 
Orthophenylene diamine (OPD) 10.O mg 
0. 1 M sodium citrate (PH 4.5) 10.0 ml 
30% H20 2 4.0ftl 
IV 
MEDIA 
Modified DMEM media (50 ml) 
DMEM 47ml 
AB Serum 2.5 ml 
Gentamycin 0.5 ml 
Brain-Heart infusion Broth (BRIB) (500ml) 
Brain-Heart infusion media 18.5 grn 
Deionized water 500 ml 
Normal Saline (lOOOml) 
NaCI 8.50 gm 
Deionized water 1000 ml 
v 
PREPARATION OF REAGENTS AND CHEMICALS 
For Tetanus Toxoid (TTl-lgG ELISA 
Preparation of Washing Solution (1:30 dilution) 30 ml 
Buffer concentrate 1.0 ml 
Distilled water 29.0 ml 
Ready-fa-use: 
• Control sera and standard sera 
• Anti-human-IgG-conjugate 
• Dilution buffer 
• Substrate 
• Stopping solution 
For Measles Virus-lgG ELISA 
For one test plate: 
Preparation of Anti-Human IgGIPOD Conjugate (1+50 dilution) 
Conjugate 250,.li 
Conjugate Buffer Microbiol 12.5 ml 
\ I 
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Preparation of Coloured Sample Buffer POD (1+20 dilution) 
Colour Solution (blue) 2.5 ml 
Sample Buffer POD 50.0 ml 
Preparation of Washing Solution POD (1+20 dilution) 
Washing Solution POD 20.0 ml 
Distilled/deionized water 400.0 ml 
Preparation of working Chromogen Solution (1+10 dilution) 
Chromogen TMB 1.0ml 
Buffer/Substrate TMB 10.O ml 
Antibodies and their dilutions used in flow cytometry (FACS) 
Antibody Dilution Company 
anti-CD3-allophycocyanine I: 100 BD 
(anti-CD3-APC), Cat#347543 
anti-CD4-peridinin chlorophyll protein 1:10 BD 
(anti-CD3-PerCP), Cat#347324 
anti-CD8-fluorescein isothyocyanate 1 :5 BD 
(anti-CD8-FITC), Cat#340692 
anti-CD 19-phycoerythrin 1 :5 BD 
(anti-CD 19-PE), Cat# 120457 
VII 
APPENDIXE 
SOFTWARES 
1. MS word 
2. Microsoft Excell 
3. Graphpad Prism (version 5.02, , USA). 
4. Flowjo (version 5.8.3) 
5. Endnote X 
6. Ascent software 
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